Immuron Limited Announces Quotation of New Securities on ASX
Immuron Limited announced the quotation of 45,472,000 ordinary fully paid securities on the ASX, enhancing market presence and providing capital for ongoing projects. The company focuses on oral immunotherapy products for gut-mediated diseases. Current analyst rating is Hold with a A$0.07 price target. Technical sentiment is Strong Sell, with a market cap of A$18.34M.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron Limited ( (AU:IMC) ) just unveiled an announcement.
Immuron Limited announced the quotation of 45,472,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance the company’s market presence and provide additional capital for its ongoing projects, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
Average Trading Volume: 591,318
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.34M
See more insights into IMC stock on TipRanks’ Stock Analysis page.
